
Tuesday, September 21, 2010
Boston Heart Lab names new CEO, closes Series C financing
By Michelle Lang
Framingham-based Boston Heart Lab has announced its appointment of new CEO Susan Hertzberg and its closing of a $10 million Series C funding round, revealed earlier this month in a regulatory filing. The financing was led by Bain Capital Ventures.
Hertzberg replaces Boston Heart Lab’s founding CEO Wolfgang Daum, who will operate as a consultant to the company. She joins Boston Heart Lab having previously served as president and CEO of Ipsogen Inc., the North American division of French cancer and molecular diagnostics firm Ipsogen SA. She has also held executive appointments at Abbott Diagnostics and management roles at Quest Diagnostics Inc. Hertzberg, who serves on the board of healthcare services firm Theracare, earned an MBA from Columbia University and a bachelor’s degree from Clemson University.
Today’s news release also noted the departure of current board members Katsu Nakajima and Bela Asztalos, and the addition of new board members Alice Limkakeng and Jeff Crisan, both of Bain Capital.
Boston Heart Lab provides cardiac diagnostic tests and disease management information, developing diagnostic information for assessing cardiac health to make meaningful treatment decisions for patients. Its lead product is a panel of 30 tests, five of which are proprietary, to diagnose heart disease or the risk of heart disease. Results can guide care for each individual patient by determining which type of drugs or other therapy might be most effective.
Boston Heart Lab began clinical operations in July 2008 after receiving its CLIA license.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Print
Email
Print Edition Stories



